Measuring the contribution of higher education to innovation capacity in the EU

The general goals of the study include the provision of evidence on the key factors determining the contribution of higher education institutions (HEIs) to innovation capabilities and expand the understanding of this contribution beyond traditional measures of the role of HEI on innovation capabilities. In this context, the general objective of the study could be verbalised as “to develop a more comprehensive model of the contribution of higher education to innovation capacity”. This objective has been operationalised into the following five specific objectives which define in detail the purpose of the study:  Specific Objective 1: Completion of a comprehensive literature review of existing means and methodologies used for capturing, interpreting and also applying data and evidence related to the contribution of higher education systems to innovation capacity;  Specific Objective 2: Critical assessment of the existing literature, including an identification of gaps and an assessment of the merits of different approaches used;  Specific Objective 3: Development of a new approach, that provides an alternative set of indicators to measure the contribution of HEIs to innovation capacity;  Specific Objective 4: Implementation of the prototype set of alternative metrics;  Specific Objective 5: Discussion of the feasibility of developing new proxies or metrics for capturing the contribution of higher education systems to innovation capacity at the EU level. In general, the objective of the project and its research tools is therefore to propose a set of indicators for future measurements of the innovation impacts of HE that is validated through the opinions of the different stakeholders in the field (through interviews, case studies and a survey)

“Development and validation of the ICAP Technology Scale to measure how teachers integrate technology into learning activities”

Previous research investigating the use of technology in school has focused mainly on the frequency of use of digital tools during lessons rather than investigating how technology is integrated with respect to different kinds of learning activities. Since the impact of technology use on learning depends on how it is used and on what activities supported by technology are implemented in lessons, a measurement instrument assessing how technology is integrated into learning activities is necessary to investigate its impact on teaching and learning processes. According to the interactive, constructive, active, and passive (ICAP) framework, which distinguishes four different learning activities based on the level of students' cognitive engagement, we developed the 12-item ICAP Technology Scale (ICAP-TS) that accounts for all four dimensions of technology integration in lessons. We used confirmatory factor analysis to validate the four-factor structure of the ICAP-TS with a sample of 1059 upper-secondary school teachers from Switzerland. We also examined reliability using classical test theory and Rasch model analysis to assess the scale's psychometric characteristics. We then analyzed the associations between the ICAP-TS and a general use frequency measure of 12 educational technologies to test the criterion validity. The results confirmed the four-factor structure of the ICAP-TS and revealed good instrument accuracy. The most difficult items to endorse are those describing the integration of technology into interactive learning activities. Furthermore, all 12 items significantly correlated with the frequency of use of 12 educational technologies. We recommend the ICAP-TS as a short and reliable measurement scale for assessing how technology is integrated into lessons, considering different learning activities based on the ICAP theoretical model

Measuring the contribution of higher education to innovation capacity in the EU. Executive Summary

There has been a massive expansion of higher education in recent decades as part of attempts to create workforces with the skills to be able to compete successfully in the context of the knowledge based economy. This emerging context demands new kinds of skills and approaches from workers to feed into industries that are evolving rapidly. Economic strength in the knowledge-based economy is driven by innovation, taking existing resources and assets and using them to do new things better and increase overall welfare levels. Whilst innovation is necessary across government, business, and civil society, universities are at the heart of attempts to improve the overall knowledge capital endowments that provide the feedstock for innovation as well as a proving ground for future innovators. At the same time, there is widespread unrest that universities are failing to respond to these new demands and are continuing to act as ‘ivory towers’ outside of rather than driving forward society (Galan-Muros, 2016). Particular concern lies on perceptions that universities have tended to expand their existing activities rather than to create new courses, pedagogies, and learning environments that best meet these needs. Where universities contribute effectively to innovation, then they can create whole new industries and sectors, and transform the fortunes of particular places. But at the moment, these conflicting narratives make it hard for policy-makers to determine whether universities (and indeed, which kinds of universities) are a boost to or a drag upon innovation capacities. A key challenge for European policy-makers is therefore distinguishing the extent to which universities are realising their potential to contribute to the emergence of the knowledge-based economy. By distinguishing which institutions are and are not realising this potential, policy-makers can developed a more nuanced set of engagement stimuli that can help to maximise this contribution and optimise the returns that European societies receive for their substantial public investments in higher education. This means that are providing the necessary education and knowledge base to deliver the ambitions of Europe 2020 and support Europe’s transition towards a successful, just and sustainable economy. This requires dealing with the uncertainty of the extent to which universities’ contribute to supporting the development of the emerging knowledge economy. Here we define ‘innovation’ as the result of the set of activities by which different kinds of knowledge are combined to create solutions and interventions to solve problems, ultimately making society a better place (a form of Schumpeterian perspective). Those societal improvements may be through: (a) raising competitiveness and creating new markets and sectors, (b) improving the delivery of public services, particularly to vulnerable social groups, or (c) reducing our environmental impacts. We seek to understand the extent to which universities are supporting ‘innovation’ as here defined to distinguish between good and bad performances, as the first step in a process by which policy-makers actively intervene to improve the performance of universities overall

Semi-quantitative and qualitative evaluation of pial leptomeningeal collateral circulation in acute ischemic stroke of the anterior circulation: the Careggi Collateral Score

Introduction: The imaging of ischemic penumbra in acute stroke is a debated issue and establishing commonly accepted criteria is difficult. Computerized tomography-perfusion studies conducted in animals have showed that the modifications occurring in the brain parenchima are part of a dynamic and progressive process involving the microcirculation. The purpose of this paper is to propose a new angiographic classification of collateral circulation in patients with acute ischemic stroke, with a possible correlation with the clinical outcome. Materials and methods: The basal angiograms of 57 patients with acute ischemic stroke is the territory of anterior circulation secondary to a major occlusion, who underwent endovascular treatment, were retrospectively reviewed and collaterals were classified according to our novel Careggi Collateral Score in 6 grades (0-6). The clinical outcome after 3 months was evaluated with modified Rankin Scale. A ROC (receiver operating characteristic) curve analysis identified a cut-off value of 1. Results: Patients with favorable collateral circulation (grades 2-5) showed a significant correlation with good clinical outcome (modified Rankin Scale ≤2). Conclusions: The Careggi Collateral Score resulted a useful tool to evaluate the chance of obtaining a favorable result with endovascular treatment in patients with acute ischemic stroke in the anterior circulation secondary to the occlusion of a major artery

A Functional Variant of the Dimethylarginine Dimethylaminohydrolase-2 Gene Is Associated with Insulin Sensitivity

Background: Asymmetric dimethylarginine (ADMA) is an endogenous inhibitor of endothelial nitric oxide synthase, which was associated with insulin resistance. Dimethylarginine dimethylaminohydrolase (DDAH) is the major determinant of plasma ADMA. Examining data from the DIAGRAM+ (Diabetes Genetics Replication And Meta-analysis), we identified a variant (rs9267551) in the DDAH2 gene nominally associated with type 2 diabetes (P =3610 25). Methodology/Principal Findings: initially, we assessed the functional impact of rs9267551 in human endothelial cells (HUVECs), observing that the G allele had a lower transcriptional activity resulting in reduced expression of DDAH2 and decreased NO production in primary HUVECs naturally carrying it. We then proceeded to investigate whether this variant is associated with insulin sensitivity in vivo. To this end, two cohorts of nondiabetic subjects of European ancestry were studied. In sample 1 (n = 958) insulin sensitivity was determined by the insulin sensitivity index (ISI), while in sample 2 (n = 527) it was measured with a euglycemic-hyperinsulinemic clamp. In sample 1, carriers of the GG genotype had lower ISI than carriers of the C allele (67633 vs.79644; P = 0.003 after adjusting for age, gender, and BMI). ADMA levels were higher in subjects carrying the GG genotype than in carriers of the C allele (0.6860.14 vs. 0.5760.14 mmol/l; P = 0.04). In sample 2, glucose disposal was lower in GG carriers as compared with C carriers (9.364.1 vs. 11.064.2 mg6Kg 21 free fat mass6min 21; P = 0.009)

Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

Background: Glucagon-like peptide 1 receptor agonists differ in chemical structure, duration of action, and in their effects on clinical outcomes. The cardiovascular effects of once-weekly albiglutide in type 2 diabetes are unknown. We aimed to determine the safety and efficacy of albiglutide in preventing cardiovascular death, myocardial infarction, or stroke. Methods: We did a double-blind, randomised, placebo-controlled trial in 610 sites across 28 countries. We randomly assigned patients aged 40 years and older with type 2 diabetes and cardiovascular disease (at a 1:1 ratio) to groups that either received a subcutaneous injection of albiglutide (30–50 mg, based on glycaemic response and tolerability) or of a matched volume of placebo once a week, in addition to their standard care. Investigators used an interactive voice or web response system to obtain treatment assignment, and patients and all study investigators were masked to their treatment allocation. We hypothesised that albiglutide would be non-inferior to placebo for the primary outcome of the first occurrence of cardiovascular death, myocardial infarction, or stroke, which was assessed in the intention-to-treat population. If non-inferiority was confirmed by an upper limit of the 95% CI for a hazard ratio of less than 1·30, closed testing for superiority was prespecified. This study is registered with ClinicalTrials.gov, number NCT02465515. Findings: Patients were screened between July 1, 2015, and Nov 24, 2016. 10 793 patients were screened and 9463 participants were enrolled and randomly assigned to groups: 4731 patients were assigned to receive albiglutide and 4732 patients to receive placebo. On Nov 8, 2017, it was determined that 611 primary endpoints and a median follow-up of at least 1·5 years had accrued, and participants returned for a final visit and discontinuation from study treatment; the last patient visit was on March 12, 2018. These 9463 patients, the intention-to-treat population, were evaluated for a median duration of 1·6 years and were assessed for the primary outcome. The primary composite outcome occurred in 338 (7%) of 4731 patients at an incidence rate of 4·6 events per 100 person-years in the albiglutide group and in 428 (9%) of 4732 patients at an incidence rate of 5·9 events per 100 person-years in the placebo group (hazard ratio 0·78, 95% CI 0·68–0·90), which indicated that albiglutide was superior to placebo (p<0·0001 for non-inferiority; p=0·0006 for superiority). The incidence of acute pancreatitis (ten patients in the albiglutide group and seven patients in the placebo group), pancreatic cancer (six patients in the albiglutide group and five patients in the placebo group), medullary thyroid carcinoma (zero patients in both groups), and other serious adverse events did not differ between the two groups. There were three (<1%) deaths in the placebo group that were assessed by investigators, who were masked to study drug assignment, to be treatment-related and two (<1%) deaths in the albiglutide group. Interpretation: In patients with type 2 diabetes and cardiovascular disease, albiglutide was superior to placebo with respect to major adverse cardiovascular events. Evidence-based glucagon-like peptide 1 receptor agonists should therefore be considered as part of a comprehensive strategy to reduce the risk of cardiovascular events in patients with type 2 diabetes. Funding: GlaxoSmithKline

Association of kidney disease measures with risk of renal function worsening in patients with type 1 diabetes

Background: Albuminuria has been classically considered a marker of kidney damage progression in diabetic patients and it is routinely assessed to monitor kidney function. However, the role of a mild GFR reduction on the development of stage 653 CKD has been less explored in type 1 diabetes mellitus (T1DM) patients. Aim of the present study was to evaluate the prognostic role of kidney disease measures, namely albuminuria and reduced GFR, on the development of stage 653 CKD in a large cohort of patients affected by T1DM. Methods: A total of 4284 patients affected by T1DM followed-up at 76 diabetes centers participating to the Italian Association of Clinical Diabetologists (Associazione Medici Diabetologi, AMD) initiative constitutes the study population. Urinary albumin excretion (ACR) and estimated GFR (eGFR) were retrieved and analyzed. The incidence of stage 653 CKD (eGFR < 60 mL/min/1.73 m2) or eGFR reduction > 30% from baseline was evaluated. Results: The mean estimated GFR was 98 \ub1 17 mL/min/1.73m2 and the proportion of patients with albuminuria was 15.3% (n = 654) at baseline. About 8% (n = 337) of patients developed one of the two renal endpoints during the 4-year follow-up period. Age, albuminuria (micro or macro) and baseline eGFR < 90 ml/min/m2 were independent risk factors for stage 653 CKD and renal function worsening. When compared to patients with eGFR > 90 ml/min/1.73m2 and normoalbuminuria, those with albuminuria at baseline had a 1.69 greater risk of reaching stage 3 CKD, while patients with mild eGFR reduction (i.e. eGFR between 90 and 60 mL/min/1.73 m2) show a 3.81 greater risk that rose to 8.24 for those patients with albuminuria and mild eGFR reduction at baseline. Conclusions: Albuminuria and eGFR reduction represent independent risk factors for incident stage 653 CKD in T1DM patients. The simultaneous occurrence of reduced eGFR and albuminuria have a synergistic effect on renal function worsening

Evaluation of a direct method for the identification and antibiotic susceptibility assessment of microrganisms isolated from blood cultures by automatic systems

The purpose of blood cultures in the septic patient is to address a correct therapeutic approach. Identification and antibiotic susceptibility test carried out directly from the bottle may give important information in short time.The introduction of the automatic instrumentation has improved the discovering of pathogens in the blood, however the elapsing time between the positive detection and the microbiological report is still along. Is the evaluation of this study a fast, easy, cheap method to be applied to the routine, which could reduce the response time in the bacteraemia diagnosis.The automatic systems Vitek Senior (bioMérieux), and Vitek 2 (bioMérieux) were used at Pio Albergo Trivulzio (Centre1) and at Istituto dei Tumori (Centre2) respectivetly.To remove blood cells, 7 ml. of the culture has been moved by vacuum sampling in a test tube and centrifuged for 10 minutes at 1000 rpm the supernatant has been further centrifuged for 10 minutes at 3000 rpm.0.5 ml. of BHI has been added to the pellet o sediment.The concentration of bacterial suspension has been fit for the inoculation. At the same time has been prepared standard cultures in suitable culture media were carried out for comparison. In the centro1 and centro2 have been isolated and identify respectively 63 and 31 Gram negative, and, 32 and 40 gram positive microorganisms have been isolated and identify in the Centre1 and Centre2 respectively.The identification Gram-negative and Gram positive microorganisms showed an agreement of 100% and 86.2% and 93.3% and 65.78% respectively between the direct and the standard method. For antibiotic susceptibility tests, 903 (Centre1) and 491 (Centre2) and 396 and 509 compounds were totally assessed in Gram negative and Gram positive bacteria respectively.The analysis has highlighted that: Centre1 has reported 0.30% very major errors (GE), 0.92% major errors (EM), 1.23% minor errors (Em). Centre 2 showed 0.57% very major errors (GE), 0.09% major errors (EM), 1.34% minor errors (Em).The low percentage of GE of EM and Em obtained, the low cost and impact in the laboratory routine justify the use of a direct method with automatic instrumentations so that it allows to set up in short times an addressed antibiotic therapy